Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19
et al., Identification of Biomarkers, New Treatments, and Vaccines for COVID-19, doi:10.1007/978-3-030-71697-4_17
, Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with.., Identification of Biomarkers, New Treatments, and Vaccines for COVID-19, doi:10.1007/978-3-030-71697-4_17
Retrospective 587 COVID+ hospitalized patients in Iran, showing no significant differences in outcomes with aspirin treatment.Although the 22% lower mortality is not statistically significant, it is consistent with the significant 12% lower mortality [6‑18%] from meta analysis of the 55 mortality results to date.
|
risk of death, 21.9% lower, RR 0.78, p = 0.56, treatment 13 of 337 (3.9%), control 28 of 250 (11.2%), adjusted per study, odds ratio converted to relative risk, multivariable, primary outcome.
|
|
risk of ICU admission, 10.5% higher, RR 1.10, p = 0.67, treatment 36 of 337 (10.7%), control 44 of 250 (17.6%), adjusted per study, odds ratio converted to relative risk, multivariable.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Vahedian-Azimi et al., 20 Jul 2021, retrospective, Iran, peer-reviewed, 9 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.